Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Tenax Therapeutics, Inc. (NASDAQ:TENX) has become one of the more unusual biotechnology special situations of August.</li><li>The company is developing oral levosimendan for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, a difficult cardiovascular condition with no approved therapy specifically targeting this population.</li><li>On August 10, the investment case appeared to break.</li></ul>

Tenax Therapeutics, Inc. (NASDAQ:TENX) has become one of the more unusual biotechnology special situations of August.The company is developing oral levosimendan for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, a difficult cardiovascular condition with no approved therapy specifically targeting this population.On August 10, the investment case appeared to break.

Tenax Therapeutics: Adar1 Bought $1.8 Million After The Phase 3 Collapse — What Could It Be Seeing Before ESC?

United States

Tenax Therapeutics, Inc. operates as a specialty pharmacuitical company. The Company develops and commercializes products for the critical care market. Tenax Therapeutics develops treatments for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) using levosimendan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tenax Therapeutics (TENX US)

Tenax Therapeutics: Adar1 Bought $1.8 Million After The Phase 3 Collapse — What Could It Be Seeing Before ESC?

Tenax Therapeutics, Inc. (NASDAQ:TENX) has become one of the more unusual biotechnology special situations of August. The company is developing...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)